迈威生物：9MW1911注射液临床试验申请获得FDA许可

Core Viewpoint - Maiwei Biotech (688062.SH) has received a Study May Proceed Notification from the FDA, allowing the clinical trial application for 9MW1911 to proceed [1] Group 1: Company Information - 9MW1911 is an innovative monoclonal antibody developed based on a high-efficiency B lymphocyte screening platform [1] - The product is classified as a Class 1 therapeutic biological product [1] - 9MW1911 has a high affinity for the ST2 receptor, which blocks the IL33/ST2 signaling pathway [1]